AMSBIO, in association with Nordmark Biochemicals, is now offering animal-free Collagenase and Neutral Protease enzymes, isolated from Clostridium histolyticum, for in vitro tissue dissociation leading to high yields of viable cells.
News
From mobile apps to digital biomarkers, transformative technologies – such as
Sioux Falls, South Dakota, United States and Cambridge, UK – 25 March 2021–Sanford Health (‘Sanford’), a leading US-based healthcare delivery system provider and Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples’ lives, today announce a genomics partnership focused on providing answers for patients and families with hard to diagnose rare diseases.
PrecisionLife today announces that it has acquired its long-term Danish technology development partner GenoKey ApS, bringing together the leaders in combinatorial analytics and large-scale genomic analysis, and enabling PrecisionLife to continue its expansion as an AI-enabled precision medicine company. Financial details of the paper-based transaction were not disclosed.
Cambridge, UK, 23 March 2021: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.
Cambridge, UK, 17 March 2021: CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro 3D liver model, whose phenotype and functions mimic that in vivo, with a range of other organs to more accurately recapitulate the multi-organ and systemic effects observed in humans.
Manufactured in dedicated clean-rooms with mandated changeovers before new production cycles - AMSBIO introduces new pHelper-Kan plasmid DNA optimized for Adeno-Associated Virus (AAV) manufacturing.
Adeno-associated virus is a non-enveloped virus that can be engineered to efficiently deliver DNA sequences of interest into target cells with a low immunogenicity. Because of these unique characteristics, AAV-mediated genome editing has emerged as a highly promising gene delivery method.
Glasgow, UK, 17 March 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round. The round was co-led by Forbion and Gilde Healthcare. Additional investors in this round include Novartis Venture Fund, and Eli Lilly and Company, joining existing investor BioMotiv and founding investor Advent Life Sciences.
Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2021 -- Inivata, a leader in liquid biopsy, will present new data on its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place on 10-15 April 2021. Data on the Company’s InVisionFirst-Lung liquid biopsy test will also be presented.
Cambridge 15th March 2021: Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to confirm Jo Parfrey as the new BBT Board Chair.
Jo has been a non-executive director on the BBT Board for over four years and has chaired the company’s Audit Committee. She follows on from Dr Andy Richards who has formally stood down from the role after many years’ service. Dr Richards remains an active supporter of the Campus.